Bicycle Therapeutics Files 8-K Report
Ticker: BCYC · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1761612
Sentiment: neutral
Topics: filing, financials, sec-report
Related Tickers: BCYC
TL;DR
BCYC filed an 8-K, mostly financial docs, no major news yet.
AI Summary
On September 14, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt. The company is incorporated in England and Wales and is listed under the SIC code for Pharmaceutical Preparations.
Why It Matters
This filing indicates Bicycle Therapeutics plc is adhering to its reporting obligations with the SEC, providing necessary financial and exhibit information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Numbers
- 20240914 — Date of Report (Earliest event reported)
- 20240919 — Filing Date (Date the report was filed with the SEC)
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- 0001761612 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- England and Wales (company) — Jurisdiction of Incorporation
- 001-38916 (company) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for Bicycle Therapeutics plc?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of September 14, 2024.
When was Bicycle Therapeutics plc incorporated?
Bicycle Therapeutics plc was incorporated in England and Wales.
What is the Standard Industrial Classification (SIC) code for Bicycle Therapeutics plc?
The SIC code for Bicycle Therapeutics plc is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Bicycle Therapeutics plc?
The SEC file number for Bicycle Therapeutics plc is 001-38916.
What is the Central Index Key (CIK) for Bicycle Therapeutics plc?
The Central Index Key (CIK) for Bicycle Therapeutics plc is 0001761612.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-09-19 08:00:22
Filing Documents
- tm2424162d1_8k.htm (8-K) — 31KB
- tm2424162d1_ex99-1.htm (EX-99.1) — 25KB
- tm2424162d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-101202.txt ( ) — 288KB
- bcyc-20240914.xsd (EX-101.SCH) — 3KB
- bcyc-20240914_def.xml (EX-101.DEF) — 26KB
- bcyc-20240914_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240914_pre.xml (EX-101.PRE) — 25KB
- tm2424162d1_8k_htm.xml (XML) — 6KB
01
Item 8.01 Other Events. On September 14, 2024, Bicycle Therapeutics plc issued a press release announcing updated clinical results for zelenectide pevedotin (formerly BT8009) in mUC, BT5528 in advanced solid tumors, and BT7480 in advanced solid tumors. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued September 14, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 19, 2024 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer